Top

Published in:

01-03-2021 | Cannabinoid | Letter to the Editor

Successful treatment of cannabinoid administration against refractory epilepsy in Batten disease: a case report

Authors: Fotini Georgiou, Panayiotis Maghsoudlou, Panagiotis Loukaidis, D. Markoullaki, Christiana Giorgi, Ioanna Christodoulou, Chrystalla Matsentidou

Published in: Neurological Sciences | Issue 3/2021

Excerpt

Dear Editor, …

Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group (2017) Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med 376:2011–2020. https://doi.org/10.1056/NEJMoa1611618CrossRefPubMed

Dolisca S-B, Mehta M, Pearce DA, Mink JW, Maria BL (2013) Batten disease: clinical aspects, molecular mechanisms, translational science, and future directions. J Child Neurol 28:1074–1100. https://doi.org/10.1177/0883073813493665CrossRefPubMedPubMedCentral

Mole SE, Cotman SL (2015) Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta 1852:2237–2241. https://doi.org/10.1016/j.bbadis.2015.05.011CrossRefPubMedPubMedCentral

Reddy DS, Golub VM (2016) The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther 357:45–55. https://doi.org/10.1124/jpet.115.230151CrossRefPubMed

Rocha L, Frías-Soria CL, Ortiz JG, Auzmendi J, Lazarowski A (2020) Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy? Epilepsia Open 5:36–49CrossRef

Szaflarski JP, Bebin EM (2014) Cannabis, cannabidiol, and epilepsy--from receptors to clinical response. Epilepsy Behav 41:277–282. https://doi.org/10.1016/j.yebeh.2014.08.135CrossRefPubMed

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR (2016) Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15:270–278. https://doi.org/10.1016/S1474-4422(15)00379-8CrossRefPubMed

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham K, Zuberi SM, GWPCARE3 Study Group (2018) Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med 378:1888–1897. https://doi.org/10.1056/NEJMoa1714631CrossRefPubMed

McCoy B, Wang L, Zak M, al-Mehmadi S, Kabir N, Alhadid K, McDonald K, Zhang G, Sharma R, Whitney R, Sinopoli K, Snead OC III (2018) A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol 5:1077–1088. https://doi.org/10.1002/acn3.621CrossRefPubMedPubMedCentral

Title: Successful treatment of cannabinoid administration against refractory epilepsy in Batten disease: a case report
Authors: Fotini Georgiou
Panayiotis Maghsoudlou
Panagiotis Loukaidis
D. Markoullaki
Christiana Giorgi
Ioanna Christodoulou
Chrystalla Matsentidou
Publication date: 01-03-2021
Publisher: Springer International Publishing
Keywords: Cannabinoid
Epilepsy
Tracheostomy
Levetiracetam
Phenobarbital
Valproate
Zonisamide
Phenobarbital
Published in: Neurological Sciences / Issue 3/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04763-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Successful treatment of cannabinoid administration against refractory epilepsy in Batten disease: a case report

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2021

Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy

Neuronal ceroid lipofuscinosis: genetic and phenotypic spectrum of 14 patients from Turkey

Holmes tremor and palatal tremor in hypertrophic olivary degeneration: involvement of brainstem

Hereditary spastic paraplegia

Prevalence, risk factors, and clinical correlations of underweight in Chinese newly diagnosed and drug-naïve patients with Parkinson’s disease

AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?